BioStock: Biosergen’s CEO: “The first patient regained his health”

In Biosergen’s Q2 report, the company  highlights the successful start of the phase Ib study with BSG005. The first patient with invasive fungal disease recovered and preserved both his lungs by avoiding surgery after being treated with BSG005, something the company describes as “very remarkable.” BioStock reached out to CEO Tine Olesen to learn more about this success and the company’s financial status.

Read the interview with Tine Olesen at biostock.se:

https://www.biostock.se/en/2024/09/biosergens-ceo-the-first-patient-regained-his-health/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/